TargetBeta
KDM1A
lysine demethylase 1A · also KIAA0601, BHC110, LSD1, AOF2 · CoREST complex subunits
2 programs in company-led studies act on KDM1A, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| bomedemstat | Merck | phase 3 | 114 running | – | a judged reading |
| LSD1 Inhibitor EXS74539rule | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Hepatic Insufficiency, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Polycythemia Vera, 1 program
- Primary Myelofibrosis, 1 program
- Small Cell Lung Carcinoma, 1 program
- Thrombocythemia, Essential, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jul 14, 2027bomedemstat · Merck · phase 3 · NCT06079879
- Mar 2029LSD1 Inhibitor EXS74539 · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals · phase 1 · NCT07517198
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.